303 related articles for article (PubMed ID: 12235454)
21. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
Suzuki K; Yanagawa T; Shibasaki T; Kaniwa N; Hasegawa R; Tohkin M
Diabetes Res Clin Pract; 2006 May; 72(2):148-54. PubMed ID: 16325295
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers.
Fischer TL; Pieper JA; Graff DW; Rodgers JE; Fischer JD; Parnell KJ; Goldstein JA; Greenwood R; Patterson JH
Clin Pharmacol Ther; 2002 Sep; 72(3):238-46. PubMed ID: 12235444
[TBL] [Abstract][Full Text] [Related]
23. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green.
Hiratsuka M; Agatsuma Y; Mizugaki M
Mol Genet Metab; 1999 Nov; 68(3):357-62. PubMed ID: 10562462
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.
Shintani M; Ieiri I; Inoue K; Mamiya K; Ninomiya H; Tashiro N; Higuchi S; Otsubo K
Clin Pharmacol Ther; 2001 Aug; 70(2):175-82. PubMed ID: 11503012
[TBL] [Abstract][Full Text] [Related]
25. Clinical consequences of cytochrome P450 2C9 polymorphisms.
Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.
Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
Clin Pharmacol Ther; 2002 Nov; 72(5):562-71. PubMed ID: 12426520
[TBL] [Abstract][Full Text] [Related]
27. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
Miners J
Pharmacogenetics; 2002 Mar; 12(2):91-2. PubMed ID: 11875362
[No Abstract] [Full Text] [Related]
28. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.
Bigler J; Whitton J; Lampe JW; Fosdick L; Bostick RM; Potter JD
Cancer Res; 2001 May; 61(9):3566-9. PubMed ID: 11325819
[TBL] [Abstract][Full Text] [Related]
29. [Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray].
Li J; Wen SY; Wang R; Chen K; Fang Y; Pei F; Wang SQ
Yao Xue Xue Bao; 2005 Aug; 40(8):695-9. PubMed ID: 16268502
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects.
Yoo HD; Kim MS; Cho HY; Lee YB
Eur J Clin Pharmacol; 2011 Sep; 67(9):889-98. PubMed ID: 21476064
[TBL] [Abstract][Full Text] [Related]
31. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients.
Surendiran A; Pradhan SC; Agrawal A; Subrahmanyam DK; Rajan S; Anichavezhi D; Adithan C
Eur J Clin Pharmacol; 2011 Aug; 67(8):797-801. PubMed ID: 21336994
[TBL] [Abstract][Full Text] [Related]
32. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
33. Role of CYP2C9 polymorphism in losartan oxidation.
Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
[TBL] [Abstract][Full Text] [Related]
34. Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3.
Iwakawa S; Miyashita K; Hashimoto Y; Kuroda T
Biol Pharm Bull; 2006 Sep; 29(9):1983-5. PubMed ID: 16946524
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
Yasar U; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Clin Pharmacol Ther; 2002 Jan; 71(1):89-98. PubMed ID: 11823761
[TBL] [Abstract][Full Text] [Related]
36. Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population.
Cho HJ; Lee SY; Kim YG; Oh SY; Kim JW; Huh W; Ko JW; Kim HG
Clin Chim Acta; 2011 Sep; 412(19-20):1831-4. PubMed ID: 21704609
[TBL] [Abstract][Full Text] [Related]
37. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.
Komatsu K; Ito K; Nakajima Y; Kanamitsu Si; Imaoka S; Funae Y; Green CE; Tyson CA; Shimada N; Sugiyama Y
Drug Metab Dispos; 2000 Apr; 28(4):475-81. PubMed ID: 10725317
[TBL] [Abstract][Full Text] [Related]
38. Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats.
Neerati P; Gade J
Eur J Pharm Sci; 2011 Feb; 42(3):285-9. PubMed ID: 21182938
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects.
Courtois P; Sener A; Herbaut C; Turc A; Malaisse WJ
Res Commun Mol Pathol Pharmacol; 1999 Feb; 103(2):211-22. PubMed ID: 10461687
[TBL] [Abstract][Full Text] [Related]
40. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
